SUMMARY  

• Use with other non-Janssen COVID-19 Vaccines
  • Currently, there are no published studies on the concomitant use of other manufacturers’ COVID-19 vaccines and ERLEADA.
  • Clinicians should use clinical judgement based on local/institutional guidelines, standards of care, and individual patient risk/benefit assessment when considering concomitant use of ERLEADA and the other COVID-19 vaccine.
  • For additional information regarding the use of other non-Janssen COVID-19 vaccines, please refer to the vaccine manufacturer.
• General Vaccination Information
  • Cancer organizations, including the National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO), and the European Society for Medical Oncology (ESMO), have published healthcare professional resources related to COVID-19 vaccination and patients with cancer, visit: NCCN COVID-19 Resources, ASCO: COVID-19 Vaccines & Patients with Cancer, and ESMO Statements on Vaccination Against COVID-19 in People with Cancer.^1-3 Please note: This list is not all inclusive and is subject to change.
  • Refer to the Centers for Disease Control (CDC) and Prevention Advisory Committee on Immunization Practices (ACIP) COVID-19 Vaccine Recommendations, Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States, and General Best Practice Guidelines for Altered Immunocompetence. For more information, including additional mRNA COVID-19 vaccine dose recommendations for patients with solid tumor malignancies receiving active treatment, visit: COVID-19 ACIP Vaccine Recommendations, Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States, and General Best Practice Guidelines for Immunization, Altered Immunocompetence.^4-6

Literature Search

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, and Derwent Drug File (and/or other resources, including internal/external databases) was conducted on 04 September 2024.